Mithra CDMO Strengthens its Management Team and Accelerates Key R&D Programs

  • Strengthening of management team with key appointments of Chief Scientific Officer and Plant Manager, to support the strategy execution of Mithra CDMO
  • Consolidation of R&D and manufacturing teams with 30% increase in highly qualified staff since the beginning of the year
  • Donesta® and PeriNesta® Phase III studies ready to begin, pending approval by authorities
  • Launch of production of Estelle® clinical validation batches for both U.S. and EU filing
  • Positive outcome of the registration procedure for Myring™, adding 15 new Market Authorizations in Europe
Liege, Belgium, 16 July 2019 – 7 :30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces it has strengthened its CDMO Management team with the appointments of Dr Graham Dixon as Chief Scientific Officer and Mr Renaat Baes as Plant Manager.

Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 29 April 2019 – 17:45 CEST – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 24,750 new shares on 24 April 2019 for an amount of EUR 84,690 as the result of the exercise of 15 subscription rights (warrants) pursuant to the warrant plan initiated on 2 March 2015.

Following this capital increase, Mithra now has 37,688,995 outstanding shares carrying voting rights (37,664,245 outstanding shares previously).

Therefore, Mithra publishes the updated following information :

  • Share capital: EUR 27,591,999.58
  • Total number of securities carrying voting rights: 37,668,995 (all ordinary shares)
  • Total number of voting rights (= denominator): 37,668,995 (all relating to ordinary shares)
  • Number of rights to subscribe securities carrying voting rights not yet issued:
    • Pursuant to the warrant plan of 2 March 2015: 620 warrants giving right to 1,023,000 shares
    • Pursuant to the warrant plan of 5 November 2018 and following the offer of new subscription rights for new members of the Management Team: 1,336,034 warrants giving right to 1,336,034 shares

Mithra wins essenscia Innovation Award 2019 for its new generation contraceptive pill, Estelle®

  • Mithra wins the Essenscia Innovation Award, the most prestigious prize for industrial innovation in Belgium
  • Jury of experts recognize the major breakthrough and worldwide potential of this new generation contraceptive pill
  • Capping more than 20 years of research and development, this award was presented by her Royal Highness, the Princess Astrid, during a ceremony at the Palace of the Academies in Brussels

Liege, Belgium, 02 April 2019 – 17:00 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it won the prestigious essenscia Innovation Award 2019. Awarded every two years by the Federation of Chemistry and Life Sciences, the Innovation Award is the most important prize for industrial innovation in Belgium. It aims to highlight the greatest innovations of Belgian industry and to encourage Belgian companies to continue to invest in innovative and sustainable products.

Mithra Demonstrates Further Estetrol’s Unique Profile at the Annual Meeting of the Endocrine Society

Liege, Belgium, 25 March 2019 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health has presented the results of a new study on Estetrol (E4) at the 101st Annual Meeting of the Endocrine Society (ENDO 2019) held from March 23 to 26 in New Orleans (U.S.)

 

Mithra Reports 2018 Annual Results

  • Strong revenue growth (+42%) with significantly improved EBITDA (record level of EUR 38.3 M vs. EUR -18.4 M in 2017) and cash position (EUR 119 M vs. EUR 36.2 M in 2017) thanks to increased business development activities
  • Strengthening Mithra’s international deployment through key partnerships with women’s health leaders
  • Clinical milestones successfully achieved for highly promising portfolio E4 (Estetrol)-based pipeline, including the 5th generation contraceptive pill Estelle® and next-generation menopause therapy Donesta®
  • Additional potential E4-based blockbuster for the underserved perimenopause market with PeriNesta™ in development (which brings Mithra’s late clinical stage pipeline to a total of 3)

Liege, Belgium, 01 March 2019– 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its results for the year ended 31 December 2018, prepared in accordance with IFRS.

Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 25 February 2019 – 17:45 CET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 24,750 new shares on 30 January 2019 for an amount of EUR 84 690 as the result of the exercise of 15 subscription rights (warrants) pursuant to the warrant plan initiated on 2 March 2015. Following this capital increase, Mithra now has 37.664.245 outstanding shares carrying voting rights (37,639,495 outsanding shares previously).

Therefore, Mithra publishes the updated following information :

  • Share capital: EUR 27,573,880.18
  • Total number of securities carrying voting rights: 37,664,245 (all ordinary shares)
  • Total number of voting rights (= denominator): 37,664,245 (all relating to ordinary shares)
  • Number of rights to subscribe securities carrying voting rights not yet issued:
    • Pursuant to the warrant plan of 2 March 2015: 635 warrants giving right to 1,047,750 shares
    • Pursuant to the warrant plan of 5 November 2018: 1,238,339 warrant giving right to 1,238,339 shares

Mithra Announces New Polymer Technology Development for a Leading Veterinarian Company

  • First veterinary R&D project concluded with one of the world’s largest animal health players, CEVA
  • Development of an innovative hormonal device for the bovine fertility market
  • Expansion of Mithra CDMO polymer technology expertise attracts new development partners

Liege, Belgium, 20 February 2019 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health announces today that it has signed a contract with the CEVA Animal Health group to develop a hormonal device for the veterinary market. CEVA Animal Health is one of the ten largest veterinary pharmaceutical groups in the world and develops products that meet the specific needs of the various sectors of this market, particularly bovines.

Mithra Strengthens Management Team With Key Appointments

  • Expansion of IR and Communications functions to support the execution of Mithra’s strategy

Liège, Belgium, 4 February 2019 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces it has strengthened its IR and Communications functions with the appointments of Ms. Alexandra Deschner as Investor Relations Officer and Ms. Maud Vanderthommen as Communications Manager.

 

Mithra announces 2019 financial calendar

Liege, Belgium, 22 January 2019 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company focused on women’s health, today announces its financial calendar for 2019 :

  • 1 March 2019 : Full Year Results 2018
  • 8 April 2019 : Annual Report 2018
  • 16 May 2019 : Annual General Shareholders Meeting
  • 19 September 2019 : Interim report 2019

This calendar and all corporate information on the Company, such as its financial statements, events or corporate presentations, is available on the Company’s website in the Investors’ section  (investors.mithra.com).

Mithra Wins BelMid Company of the Year 2018

Liège, Belgium, 18 January 2019 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, has been awarded BelMid Company of the Year 2018 by Euronext Brussels at its annual New Year’s Ceremony held in Brussels last night.